Development of Lyophilised Eudragit^® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration

• Main Authors: Rosamaria Lombardo (Author), Marika Ruponen (Author), Jarkko Rautio (Author), Carla Ghelardini (Author), Lorenzo Di Cesare Mannelli (Author), Laura Calosi (Author), Daniele Bani (Author), Riikka Lampinen (Author), Katja M. Kanninen (Author), Anne M. Koivisto (Author), Elina Penttilä (Author), Heikki Löppönen (Author), Rosario Pignatello (Author)
• Format: Book
• Published: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large...